RNA stock forecast, quote, news & analysis
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies... Show more
Why Atrium Therapeutics (RNA) Stock Is Down -10% in the Last 30 Days
Key Takeaways
- RNA shares have fallen roughly 10% over the past 30 days, from a closing price near $8.95 in mid-September to about $8.05 at the latest reading.
- The decline was driven primarily by sentiment spillover from Novartis's late-stage clinical setbacks in early September, which renewed scrutiny of the antibody-oligonucleotide conjugate (AOC) platform that underpins Atrium's technology.
- Over the past quarter, the stock has dropped from around $11.30 in early August after peaking near $14.60 on September 3, a materially larger decline than the 30-day figure.
- Atrium remains an independent, cash-funded precision cardiology company whose lead programs, ATR 1072 and ATR 1086, were not directly affected by Novartis's trial results.
- Upcoming catalysts include the planned IND submission for ATR 1072 in the second half of 2026 and progress on the Bristol Myers Squibb collaboration.
Atrium Therapeutics (RNA) Company Overview and Market Position
Atrium Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing targeted RNA therapeutics designed for delivery to the heart to treat rare, life-threatening genetic cardiomyopathies. The company's proprietary platform combines the tissue selectivity of monoclonal antibodies with the precision of oligonucleotides to enable non-viral delivery of small interfering RNA (siRNA) directly to cardiac tissue.
Atrium was established in connection with Novartis's approximately $12 billion acquisition of Avidity Biosciences, which closed on February 27, 2026. As part of that transaction, Avidity's early-stage precision cardiology programs were separated into Atrium, which became an independent, publicly traded company and assumed the Nasdaq ticker RNA. The company launched with roughly $270 million in cash and a pipeline consisting of two lead candidates, ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN (phospholamban) cardiomyopathy, along with two undisclosed research-stage targets in rare cardiomyopathies.
Atrium Therapeutics (RNA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, RNA has declined approximately 10%, falling from a closing price near $8.95 in mid-September to about $8.05 at the latest available reading. The move has been choppy rather than linear, with the stock trading in a range roughly between $7.50 and $8.50 through much of October.
The quarterly picture is more pronounced. The stock entered the period trading around $11.30 in early August, climbed to a peak near $14.60 on September 3, and then declined sharply. From that September peak, shares have fallen roughly 45%, while the decline from early August levels is approximately 29%. The bulk of the losses were concentrated in the first two weeks of September, when the broader reassessment of RNA-delivery platforms weighed heavily on the stock.
What Drove RNA Stock Price in the Last 30 Days
The primary catalyst behind the recent weakness in RNA shares was not Atrium-specific news but rather a sector-wide reassessment triggered by Novartis. On September 4, 2026, Novartis disclosed that pelacarsen had missed its primary endpoint in a Phase 3 cardiovascular study. Days later, on September 8, Novartis announced that del-desiran (delpacibart etedesiran), the lead asset from its Avidity acquisition, failed to meet its primary endpoint in the Phase 3 HARBOR trial for myotonic dystrophy type 1.
Because del-desiran was the centerpiece of Novartis's $12 billion Avidity acquisition and the most advanced AOC asset in the industry, its failure prompted investors to re-examine the value of the broader AOC technology platform. Atrium's cardiac-delivery platform was originally developed at Avidity and relies on the same underlying approach, so the stock fell in sympathy even though Atrium's own lead programs were not directly implicated in the trial results.
The selloff was compounded by technical pressure. In late September, RNA crossed below its 200-day moving average, an event that coincided with elevated trading volume and continued downward momentum as investors awaited greater clarity on the platform's clinical viability.
What Drove RNA Stock Performance Over the Last Quarter
The quarter's larger narrative reflects a sharp shift in sentiment around the AOC platform. Earlier in the period, Atrium's independent trajectory was a positive factor: the company earned a $15 million milestone payment from its collaboration with Bristol Myers Squibb and progressed ATR 1072 toward the clinic, including completing GLP toxicology studies and holding pre-IND discussions with regulators.
That momentum was overshadowed by Novartis's clinical setbacks in early September. The del-desiran failure in particular raised broader questions about whether the AOC approach could translate promising delivery technology into clinical benefit, and the read-through pressured companies with similar RNA-delivery strategies. As a result, RNA gave back its early-quarter gains and moved well below its longer-term moving averages, reflecting a more cautious valuation of the platform despite Atrium's independence from Novartis.
Trending AI Robots
Investors tracking fast-moving stocks like RNA can benefit from automated tools designed to navigate shifting sentiment. Tickeron's Trending AI Robots page highlights a curated selection of AI trading bots from a broader universe of hundreds of bots trading thousands of tickers. Only the top-performing and most relevant bots appear in this section, and each bot differs in strategy, timeframe, and performance metrics, allowing users to compare approaches that align with their own objectives. For those seeking a data-driven way to monitor market momentum, exploring these trending strategies may offer a useful starting point.
RNA Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important near-term catalyst for RNA is the planned Investigational New Drug (IND) submission for ATR 1072 in the second half of 2026, which would clear the way for a Phase 1/2 clinical trial subject to regulatory clearance. Progress on ATR 1086, including IND-enabling studies during 2026 and a targeted IND filing in 2027, will also be closely watched.
Beyond Atrium's own pipeline, investors will monitor whether sentiment toward AOC and RNA-delivery platforms stabilizes following Novartis's September setbacks, as well as any additional details from Novartis's analysis of the HARBOR dataset. The company's collaboration with Bristol Myers Squibb, which carries up to approximately $1.35 billion in research and development milestone payments, remains a key source of potential non-dilutive funding. Finally, quarterly financial updates and the company's cash position, reported at $267.8 million as of March 31, 2026, will remain important indicators of its ability to fund operations through key clinical milestones.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RNA sees its Stochastic Oscillator ascends from oversold territory
On October 21, 2026, the Stochastic Oscillator for RNA moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 49 instances where the indicator left the oversold zone. In 43 of the 49 cases the stock moved higher in the following days. This puts the odds of a move higher at over 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RNA's RSI Oscillator exited the oversold zone, 27 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on RNA as a result. In 64 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for RNA just turned positive on October 07, 2026. Looking at past instances where RNA's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
Following a +5.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNA advanced for three days, in 197 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for RNA entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.638) is normal, around the industry mean (2.988). P/E Ratio (-1.471) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (4.537) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. RNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in the research and development of biopharmaceutical products
Industry Biotechnology